IDALISSIE PEGUERO: Open Payments
NPI 1689154437 · NEWARK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$759 in 30 payments from 10 companies in 2025. Trend: 2023 $125 · 2024 $615 · 2025 $759
Food & beverage: $759
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 8 | $344 |
| Neurocrine BioSciences, Inc. | 6 | $107 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| E.R. Squibb & Sons, L.L.C. | 1 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Lundbeck LLC | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
Products named: LYBALVI, INGREZZA, ARISTADA, REXULTI, COBENFY, AUSTEDO XR, VIVITROL, FANAPT.
Industry payments across NJ — which companies pay providers there.
